Benjamin F. Edwards & Company Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,237 shares of the biopharmaceutical company’s stock after selling 960 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Gilead Sciences were worth $2,180,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also modified their holdings of the company. WINTON GROUP Ltd grew its stake in Gilead Sciences by 16.4% in the first quarter. WINTON GROUP Ltd now owns 7,674 shares of the biopharmaceutical company’s stock valued at $579,000 after purchasing an additional 1,079 shares in the last quarter. Principal Financial Group Inc. grew its stake in Gilead Sciences by 5.3% in the first quarter. Principal Financial Group Inc. now owns 2,945,595 shares of the biopharmaceutical company’s stock valued at $222,068,000 after purchasing an additional 148,398 shares in the last quarter. Summit Trail Advisors LLC grew its stake in Gilead Sciences by 40.9% in the first quarter. Summit Trail Advisors LLC now owns 7,808 shares of the biopharmaceutical company’s stock valued at $348,000 after purchasing an additional 2,265 shares in the last quarter. Brown Advisory Inc. grew its stake in Gilead Sciences by 15.3% in the first quarter. Brown Advisory Inc. now owns 60,197 shares of the biopharmaceutical company’s stock valued at $4,538,000 after purchasing an additional 8,006 shares in the last quarter. Finally, Gulf International Bank UK Ltd grew its stake in Gilead Sciences by 2.4% in the second quarter. Gulf International Bank UK Ltd now owns 423,972 shares of the biopharmaceutical company’s stock valued at $30,034,000 after purchasing an additional 10,026 shares in the last quarter. Institutional investors and hedge funds own 78.23% of the company’s stock.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total value of $3,708,000.00. Following the completion of the sale, the director now owns 3,067,762 shares of the company’s stock, valued at $227,505,229.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 150,000 shares of company stock valued at $11,502,500 in the last ninety days. Insiders own 1.16% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The company had revenue of $5.60 billion during the quarter, compared to analysts’ expectations of $5.44 billion. During the same quarter in the previous year, the firm earned $2.27 earnings per share. As a group, analysts predict that Gilead Sciences, Inc. will post 6.6 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be given a $0.57 dividend. The ex-dividend date is Thursday, December 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.22%. Gilead Sciences’s dividend payout ratio is currently 26.64%.
GILD has been the topic of a number of recent research reports. BidaskClub upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, October 11th. Mizuho restated a “buy” rating and issued a $94.00 target price on shares of Gilead Sciences in a research note on Friday, August 10th. Piper Jaffray Companies set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, September 12th. ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Friday, September 28th. Finally, Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a research note on Wednesday, July 18th. Thirteen investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $87.84.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Story: Price to Earnings Ratio (PE)
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.